BiotechTube

Fluconazole + Amphotericin B

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meningitis, Cryptococcal

Conditions

Meningitis, Cryptococcal, HIV Infections

Trial Timeline

— → —

NCT ID
NCT00001017

About Fluconazole + Amphotericin B

Fluconazole + Amphotericin B is a phase 3 stage product being developed by Pfizer for Meningitis, Cryptococcal. The current trial status is completed. This product is registered under clinical trial identifier NCT00001017. Target conditions include Meningitis, Cryptococcal, HIV Infections.

What happened to similar drugs?

2 of 20 similar drugs in Meningitis, Cryptococcal were approved

Approved (2) Terminated (0) Active (18)
🔄RotaTeq® + NeisVac-C®MerckPhase 3
🔄Meningococcal ACWY conjugate vaccineNovartisPhase 3
✅Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
🔄Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
🔄Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and MenveoNovartisPhase 3
🔄Meningococcal ACWY conjugate vaccineNovartisPhase 3
🔄Hib-CRM197 + Hib-TTNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00002074Pre-clinicalCompleted
NCT00002068Pre-clinicalCompleted
NCT00001017Phase 3Completed
NCT00002277Phase 3Completed

Competing Products

20 competing products in Meningitis, Cryptococcal

See all competitors
ProductCompanyStageHype Score
RotaTeq® + NeisVac-C®MerckPhase 3
40
DaptomycinMerckPre-clinical
18
Meningococcal ACWY conjugate vaccineNovartisPhase 3
40
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
43
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
40
Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and MenveoNovartisPhase 3
40
Meningococcal ACWY conjugate vaccineNovartisPhase 3
40
MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + VaricellaNovartisPhase 2
35
Hib-CRM197 + Hib-TTNovartisPhase 3
40
Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate VaccineNovartisPhase 3
40
MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvantedNovartisPhase 2
35
meningococcal B vaccine & meningococcal ACYW conjugate vaccineNovartisPhase 2
35
Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosineNovartisPhase 2
27
4CMenBNovartisApproved
43
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccineNovartisPhase 3
40
Meningococcal (group B) multicomponent recombinant adsorbed vaccineNovartisPhase 3
40
MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose)NovartisPhase 3
40
MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A VirusNovartisPhase 3
40
Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years)NovartisPhase 3
40
Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyreticNovartisPhase 2
35